The affirmation is based on several positive and negative factors, including the health system’s leading market position, recovering volume trends, weak cash levels, high leverage and moderate capital needs. Moody’s also acknowledged that MaineGeneral’s profitability will remain highly reliant on 340B drug discount savings and its contract pharmacy business, which has come under regulatory scrutiny.
The outlook is stable, reflecting Moody’s expectation that MaineGeneral will sustain its operating performance and liquidity levels.
More articles on healthcare finance:
Hospital uncompensated care surges 14% to $1.1B in Wisconsin
Mayo Clinic gets $10M donation to support 5 initiatives
12 recent hospital, health system outlook and credit rating actions
